In this 2-part animated video series, GU cancer genomics expert Dr Alexander Wyatt and pathologist Prof. Frédéric Bibeau share their recommendations and tips on how to optimise genomic testing in prostate cancer and gastric cancer.

 

Each video comes with an accompanying slide set that you can download for more information.

In this 2-part animated video series, GU cancer genomics expert Dr Alexander Wyatt and pathologist Prof. Frédéric Bibeau share their recommendations and tips on how to optimise genomic testing in prostate cancer and gastric cancer.

 

Each video comes with an accompanying slide set that you can download for more information.

In this animated video, GU cancer genomics expert Dr Alexander Wyatt shares recommendations from the guidelines, and his best tips for optimising precision oncology in prostate cancer.

 

Multi-gene germline and somatic testing is required for the identification of gene alterations in advanced prostate cancer. Both tissue and liquid biopsy (ctDNA) can be used for somatic testing, but it’s important for HCPs to know when to use liquid biopsy and how to conserve the quality of tissue samples.

 

Dr Wyatt addresses these questions and highlights other key points, including:

  • Common genomic alterations and implications in prostate cancer
  • When to order biomarker testing
  • Samples that can be used for somatic and germline testing
  • Potential challenges and recommendations to reduce the limitations of testing and interpreting results

 

Clinical takeaways

  • It is important to consider that different types of samples are needed for somatic and germline testing
  • Genomic biomarker testing is required to help with treatment decision making and for understanding inherited cancer risk
  • Next-generation sequencing of multiple genes is the gold-standard method for both germline and tumour (somatic) testing in prostate cancer
  • Alterations in HRR genes and MMR pathway genes in advanced prostate cancer can predict response to targeted therapies
  • Know how to navigate pre-analytical phase challenges, including how to collect, store, process and prepare the samples
  • Be able to include all relevant biomarkers in the test request and tests​
  • Understand the diagnostic modalities, and the role of biomarkers in oncology​
  • Be able to implement or improve the leading role of the pathologist on the MDT​

Dr. Wyatt is an associate professor in Urologic Sciences at the University of British Columbia, Canada. He is a senior research scientist at the Vancouver Prostate Centre and a senior scientist at BC Cancer. Dr. Wyatt has a DPhil in genetics from the University of Oxford. His research goals are to identify associations between genomic alterations and patient outcomes in metastatic prostate and bladder cancer, and to translate these findings into clinical biomarkers. Dr. Wyatt has developed novel laboratory and computational techniques to study plasma circulating tumour DNA (ctDNA). Through application of these methods to clinical trial cohorts, his team has demonstrated that ctDNA is highly representative of metastatic lesions, and that somatic alterations detected in ctDNA can help predict prostate cancer therapy resistance or response.

In this animated video, expert Prof. Frédéric Bibeau shares the guideline recommendations and best tips for precision oncology in gastric cancer, including: 

  • Relevant biomarkers and implications in gastric cancer
  • Who, when, and how to order biomarker testing
  • Techniques that are used for biomarker testing in gastric cancer
  • Challenges and recommendations to optimise biomarker assessment

 

Clinical takeaways

  • It is paramount to have enough samples to perform all the tests needed, starting with diagnosis
  • Order the right biomarkers to help with treatment decision-making
  • In gastric cancer, the use of IHC and ISH are the main techniques for precision medicine in 2024
  • HER2 status, PD-L1 and MMR are crucial for treatment decisions in 2024
  • Know how to navigate pre-analytical phase challenges, including how to collect, store, process and prepare the samples​ 
  • Be able to include all relevant biomarkers in the test request and tests​ 
  • Understand the diagnostic modalities, and the role of biomarkers in oncology​ 
  • Be able to implement or improve the leading role of the pathologist on the MDT​ 

Frédéric Bibeau, MD, PhD, is a Professor of Pathology at the head of the Pathology Department of the Besançon University Hospital, Franche-Comté University. He is involved in translational research, in immuno-oncology of solid tumors and in gastrointestinal tumor pathology, notably colorectal cancer, both at the diagnostic and research levels. He is responsible for several long courses in pathology and molecular pathology, notably of the GI tract. Since ten years his work has been focused on rectal cancer, microsatellite unstable colorectal cancer, liver metastases after induction treatment, peritoneal carcinomatosis and predictive factors linked to targeted therapies and immunotherapy. He also involved in national and international groups specialized in rare tumors of the peritoneum. He was one of two coordinators of the BIG-RENAPE network, corresponding to a biological and clinical database dedicated to peritoneal carcinomatosis of digestive origin.

Professor Bibeau is author or co-author of 213 publications. He belongs to the board of national and international journals. He is a member of the French Society of Pathology, the International Academy of Pathology, the French Federation of Digestive Oncology (FFCD). He has been an active member of the European Society of Medical Oncology (ESMO) and the ESMO-Precision-Medicine working group.

Prof. Frédéric Bibeau has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, MSD and Sanofi. 

 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology 
ADCs in HR+/HER2- metastatic breast cancer

Optimising treatment strategies and AE management

Experts
Dr Barbara Pistilli
Endorsed by
GRASP
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
podcast Podcast

Episode

2

of 2

episode
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 2

Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer

Experts
Dr Eric Singhi, Dr Isabel Preeshagul, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 18 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Emerging molecular testing paradigms in NSCLC management

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
animated-video Animated Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer with ESR1-mut tumors

An overview of the EMERALD subgroup analyses

Experts
Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Apr 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast

Episode

1

of 2

episode
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 1

A medical oncologist and a pathologist share their perspectives on best practices in identifying HER2-directed NSCLC

Experts
Prof. Fernando López-Ríos, MD, PhD, Dr Devika Das, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Survey findings presented at ONS 2025 and published in the journal Healthcare

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 7 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.